AR073993A1 - Compuesto de pirazolilaminopiridina, composicion farmaceuticamente aceptable que lo comprende y su uso para preparar un medicamento util para tratar el cancer - Google Patents
Compuesto de pirazolilaminopiridina, composicion farmaceuticamente aceptable que lo comprende y su uso para preparar un medicamento util para tratar el cancerInfo
- Publication number
- AR073993A1 AR073993A1 ARP090104137A AR073993A1 AR 073993 A1 AR073993 A1 AR 073993A1 AR P090104137 A ARP090104137 A AR P090104137A AR 073993 A1 AR073993 A1 AR 073993A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylene
- alkoxy
- pharmaceutically acceptable
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyridine Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Compuesto de pirazolilaminopiridina de formula (1) o una sal del mismo, en el que R1 es halo, CF3 alquilo C1-6, isopropenilo, alquileno C2-6-cicloalquilo C3-6, alcoxi C1-6 o ciano, en R2, cuando p es distinto de 0, cada R2 es independientemente F, CI, CF3, metilo, metoxi, CH2CF3, -(X)q-alquileno C1-4-R4, -(X-alquileno C1-4)q-NR5-C(O)-R6, -(X-alquileno C1-4-)q-(NR5)q-SOx-R7, -(X-alquileno C1-4)q-Y-N(R8)2, un grupo heterocicloalquil de 5 a 6 miembros-(R9)q o un grupo heteroaril de 5 a 6 miembros-(R10)r; R3 es H, cicloalquilo C3-6, alquilo C1-6, alcoxi C1-6, alquileno C1-6-R4, O-alquileno C1-6-R4, o, los grupos R3, junto con Z, forman un anillo cíclico de 5 a 6 miembros opcionalmente sustituido con metilo, alquileno C1-4-R4 o cicloalquilo C3-6; R4 es H, -(Q)q-N(R8)2, OH, SH, alcoxi C1-6, tioalquilo C1-6 o un grupo heterocicloalquil de 5 a 6 miembros-(R9)q; R5 es H o alquilo C1-6; R6 es H, alquilo C1-6, alcoxi C1-6, N(R8)2 o un grupo heteroaril de 5 a 6 miembros-(R10)r; R7 es alquilo C1-6, fenil-(R9)q o heteroaril de 5 a 6 miembros-(R10)r; R8 es independientemente H, alquilo C1-6, -O-alquilo C1-6 o, junto con el átomo de nitrogeno al que están unidos, forman un grupo heterocicloalquilo de 5 o 6 miembros; R9 es H, alquilo C1-6, alcoxi C1-6, -(Q)q-N(R8)2, -Q-alquilo C1-6, -alquil C1-6-R4 o heterocicloalquilo de 5 a 6 miembros; R10 es H, alquilo C1-6, alcoxi C1-6 o -Q-alquilo C2-6; R11 es alquilo C1-6, CF3, -CH2CF3, -(Q)q-alquileno C1-4-R4, -Q-N(R8)2, fenil-(R5)s-, un grupo heterocicloalquil de 5 a 6 miembros-(R9)q o un grupo heteroaril de 5 a 6 miembros-(R10)r; R12 es H, alquilo C1-6, F, CI, CF3, OH, CN, nitro, COOH, -COO-alquilo C1-6, -Y-N(R8)2, cicloalquil C3-6-R14, -(X)q-alquileno C1-6-R4, -(X-aIquileno C1-6)q-NR5-C(O)-R6, -(X-aIquileno C1-6)q-(NR5)q-SOx-R7, -(X-alquileno C1-6)q-Y-N(R8)2, heterocicloalquil-(R9)q, heteroaril-(R10)r o fenil-(R15)s; R13 es H, F, CI, alquilo C1-6 o cicloalquilo C3-6, o R12 y R13, junto con los átomos de carbono a los que están unidos, forman un grupo carbocicloalquilo o heterocicloalquilo condensado de 5 o 6 miembros; R14 es independientemente H, alquilo C1-6, -NR5-SO2-R7, -Y-N(R8)2 o -(X)q-alquileno C1-6-R4; cada R15 es independientemente F, CI, CF3, alquilo C1-3 o alcoxi C1-3; p es 0, 1, 2 o 3; q es 0 o 1; r es 0, 1 o 2; s es 0, 1, 2 o 3; x es 1 o 2; Q es -C(O)-, -S(O)- o -SO2-; X es NR5, O, S, -S(O)- o -SO2-; Y es un enlace, SO2 o C(O); y Z es N o CR5. Composicion farmacéuticamente aceptable que comprende dicho compuesto, o una sal farmacéuticamente aceptable del mismo. Uso de dicho compuesto, o una sal farmacéuticamente aceptable del mismo, para preparar un medicamento util para tratar el cáncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10856808P | 2008-10-27 | 2008-10-27 | |
| US17851709P | 2009-05-15 | 2009-05-15 | |
| US24243209P | 2009-09-15 | 2009-09-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR073993A1 true AR073993A1 (es) | 2010-12-15 |
Family
ID=42132177
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090104137 AR073993A1 (es) | 2008-10-27 | 2009-10-27 | Compuesto de pirazolilaminopiridina, composicion farmaceuticamente aceptable que lo comprende y su uso para preparar un medicamento util para tratar el cancer |
Country Status (36)
| Country | Link |
|---|---|
| US (6) | US20100113475A1 (es) |
| EP (1) | EP2421537B1 (es) |
| JP (1) | JP5642689B2 (es) |
| KR (1) | KR101512217B1 (es) |
| CN (1) | CN102264371B (es) |
| AR (1) | AR073993A1 (es) |
| AU (1) | AU2009320144B2 (es) |
| BR (1) | BRPI0920053B8 (es) |
| CA (1) | CA2741760C (es) |
| CL (1) | CL2011000933A1 (es) |
| CO (1) | CO6361929A2 (es) |
| CR (1) | CR20110264A (es) |
| CY (1) | CY1116399T1 (es) |
| DK (1) | DK2421537T3 (es) |
| DO (1) | DOP2011000113A (es) |
| EA (1) | EA021927B1 (es) |
| ES (1) | ES2539835T3 (es) |
| HK (1) | HK1161680A1 (es) |
| HR (1) | HRP20150531T1 (es) |
| IL (1) | IL212444A (es) |
| JO (1) | JO3067B1 (es) |
| MA (1) | MA32727B1 (es) |
| MX (1) | MX2011004369A (es) |
| MY (1) | MY161890A (es) |
| NZ (1) | NZ592477A (es) |
| PE (1) | PE20110941A1 (es) |
| PL (1) | PL2421537T3 (es) |
| PT (1) | PT2421537E (es) |
| RS (1) | RS54045B1 (es) |
| SG (1) | SG195608A1 (es) |
| SI (1) | SI2421537T1 (es) |
| SM (1) | SMT201500157B (es) |
| TW (1) | TWI454467B (es) |
| UY (1) | UY32200A (es) |
| WO (1) | WO2010062578A1 (es) |
| ZA (1) | ZA201102892B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8338441B2 (en) | 2009-05-15 | 2012-12-25 | Gilead Sciences, Inc. | Inhibitors of human immunodeficiency virus replication |
| US20120244141A1 (en) | 2010-09-28 | 2012-09-27 | Boehringer Ingelheim International Gmbh | Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors |
| MX2013008654A (es) * | 2011-01-26 | 2013-09-02 | Glaxosmithkline Intellectual Property Ltd | Combinaciones. |
| ES2691673T3 (es) | 2011-02-17 | 2018-11-28 | Cancer Therapeutics Crc Pty Limited | Inhibidores de Fak |
| DK2675794T3 (da) | 2011-02-17 | 2019-05-06 | Cancer Therapeutics Crc Pty Ltd | Selektive fak-inhibitorer |
| US9192604B2 (en) | 2011-06-28 | 2015-11-24 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of administration and treatment |
| WO2015054477A1 (en) | 2013-10-09 | 2015-04-16 | The General Hospital Corporation | Methods of diagnosing and treating b cell acute lymphoblastic leukemia |
| MX2018000288A (es) | 2015-06-29 | 2018-11-09 | Verastem Inc | Composiciones terapeuticas, combinaciones y metodos de uso. |
| CN108948019B (zh) * | 2017-05-18 | 2022-07-08 | 广东东阳光药业有限公司 | 黏着斑激酶抑制剂及其用途 |
| WO2019117813A1 (en) * | 2017-12-15 | 2019-06-20 | National University Of Singapore | Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis |
| US20210030703A1 (en) | 2018-03-12 | 2021-02-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of caloric restriction mimetics for potentiating chemo-immunotherapy for the treatment of cancers |
| CN108912095B (zh) * | 2018-08-09 | 2019-08-20 | 广州安岩仁医药科技有限公司 | 苯并咪唑类化合物及其制备方法和应用 |
| EP3856190A4 (en) * | 2018-09-27 | 2022-09-21 | Dana Farber Cancer Institute, Inc. | DEGRADATION OF FAK OR FAK AND ALK BY CONJUGATION OF FAK AND ALK INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE |
| CN113387947B (zh) * | 2021-07-12 | 2022-07-01 | 中国科学院成都生物研究所 | 调节***受体合成活性的吡唑并吡啶衍生物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US166139A (en) * | 1875-07-27 | Improvement in dental pluggers | ||
| AU760008B2 (en) | 1998-09-08 | 2003-05-08 | Agouron Pharmaceuticals, Inc. | Modifications of the VEGF receptor-2 protein and methods of use |
| US7102009B2 (en) * | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
| CA2533320A1 (en) * | 2003-08-15 | 2006-02-24 | Novartis Ag | 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| GB0419160D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| EP1746096A1 (en) * | 2005-07-15 | 2007-01-24 | 4Sc Ag | 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer |
| ES2485040T3 (es) * | 2007-03-16 | 2014-08-12 | The Scripps Research Institute | Inhibidores de cinasa de adhesión focal |
| WO2009105498A1 (en) * | 2008-02-19 | 2009-08-27 | Smithkline Beecham Corporation | Anilinopyridines as inhibitors of fak |
| ES2472323T3 (es) * | 2008-06-17 | 2014-06-30 | Astrazeneca Ab | Compuestos de piridina |
-
2009
- 2009-10-25 JO JOP/2009/0395A patent/JO3067B1/ar active
- 2009-10-26 TW TW98136145A patent/TWI454467B/zh not_active IP Right Cessation
- 2009-10-26 UY UY32200A patent/UY32200A/es not_active Application Discontinuation
- 2009-10-27 SG SG2013079579A patent/SG195608A1/en unknown
- 2009-10-27 US US12/606,390 patent/US20100113475A1/en not_active Abandoned
- 2009-10-27 US US13/126,064 patent/US20110207743A1/en not_active Abandoned
- 2009-10-27 MY MYPI2011001828A patent/MY161890A/en unknown
- 2009-10-27 CN CN2009801526261A patent/CN102264371B/zh active Active
- 2009-10-27 KR KR1020117011999A patent/KR101512217B1/ko active IP Right Grant
- 2009-10-27 BR BRPI0920053A patent/BRPI0920053B8/pt active IP Right Grant
- 2009-10-27 ES ES09829580.1T patent/ES2539835T3/es active Active
- 2009-10-27 RS RS20150365A patent/RS54045B1/en unknown
- 2009-10-27 SI SI200931192T patent/SI2421537T1/sl unknown
- 2009-10-27 WO PCT/US2009/062163 patent/WO2010062578A1/en active Application Filing
- 2009-10-27 DK DK09829580.1T patent/DK2421537T3/da active
- 2009-10-27 AR ARP090104137 patent/AR073993A1/es not_active Application Discontinuation
- 2009-10-27 JP JP2011533421A patent/JP5642689B2/ja active Active
- 2009-10-27 EP EP20090829580 patent/EP2421537B1/en active Active
- 2009-10-27 PE PE2011000920A patent/PE20110941A1/es not_active Application Discontinuation
- 2009-10-27 CA CA2741760A patent/CA2741760C/en active Active
- 2009-10-27 EA EA201170617A patent/EA021927B1/ru not_active IP Right Cessation
- 2009-10-27 PT PT98295801T patent/PT2421537E/pt unknown
- 2009-10-27 AU AU2009320144A patent/AU2009320144B2/en not_active Ceased
- 2009-10-27 NZ NZ59247709A patent/NZ592477A/xx not_active IP Right Cessation
- 2009-10-27 PL PL09829580T patent/PL2421537T3/pl unknown
- 2009-10-27 MX MX2011004369A patent/MX2011004369A/es active IP Right Grant
-
2011
- 2011-04-17 IL IL212444A patent/IL212444A/en not_active IP Right Cessation
- 2011-04-18 ZA ZA2011/02892A patent/ZA201102892B/en unknown
- 2011-04-22 MA MA33791A patent/MA32727B1/fr unknown
- 2011-04-26 CL CL2011000933A patent/CL2011000933A1/es unknown
- 2011-04-27 DO DO2011000113A patent/DOP2011000113A/es unknown
- 2011-04-29 US US13/097,271 patent/US20110269774A1/en not_active Abandoned
- 2011-05-11 CO CO11058067A patent/CO6361929A2/es active IP Right Grant
- 2011-05-17 CR CR20110264A patent/CR20110264A/es unknown
-
2012
- 2012-03-05 HK HK12102201.7A patent/HK1161680A1/xx not_active IP Right Cessation
-
2013
- 2013-10-07 US US14/047,688 patent/US9012479B2/en active Active
-
2015
- 2015-03-30 US US14/672,477 patent/US20150265589A1/en not_active Abandoned
- 2015-05-18 HR HRP20150531TT patent/HRP20150531T1/hr unknown
- 2015-05-22 CY CY20151100462T patent/CY1116399T1/el unknown
- 2015-07-03 SM SM201500157T patent/SMT201500157B/xx unknown
- 2015-10-20 US US14/887,763 patent/US9446034B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR073993A1 (es) | Compuesto de pirazolilaminopiridina, composicion farmaceuticamente aceptable que lo comprende y su uso para preparar un medicamento util para tratar el cancer | |
| HRP20230162T1 (hr) | Heteroarilni inhibitori enzima pde4 | |
| AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
| ES2626555T3 (es) | Pyridone amides como moduladores de canales de sodio | |
| AR081390A1 (es) | Compuestos de morfolina, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el antagonismo del receptor mineralocorticoide (mra) | |
| AR120896A1 (es) | COMPUESTO DE PIRIDAZINIL-TIAZOLCARBOXAMIDA COMO INHIBIDORES DE DGKz | |
| AR109958A1 (es) | Lactamas bicíclicas de piridona y sus métodos de uso | |
| AR083367A1 (es) | Compuestos de tipo quinazolinona como antagonistas de crth | |
| AR095192A1 (es) | Quinolina y quinazolinamidas como modulares de canales de sodio | |
| AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
| EA201591429A1 (ru) | 2,3-дизамещенные производные 1-ацил-4-амино-1,2,3,4-тетрагидрохинолинов и их применение в качестве ингибиторов бромодомена | |
| AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
| AR081830A1 (es) | Activadores de guanilato ciclasa soluble, composiciones farmaceuticas que los comprenden y sus usos | |
| BR112014000563A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| AR068846A1 (es) | Compuestos derivados de pirrolo (2,3d)-pirimidina inhibidores de la actividad de pkb, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos como agentes anticancer | |
| RS54708B1 (en) | ARYLETINYL DERIVATIVES | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| RS54288B1 (en) | SUBSTITUTED TRIAZOLOPYRIDINES AND THEIR USE AS TTK INHIBITORS | |
| EA201591703A1 (ru) | Замещенные 2-азабициклы и их применение в качестве модуляторов рецепторов орексина | |
| AR082153A1 (es) | N-sulfonilbenzamidas utiles como inhibidor del canal de sodio | |
| AR061858A1 (es) | Compuestos heterociclicos de fosfonatos y fosfinatos, composiciones farmaceuticas que los contienen y usos como agentes antidiabeticos. | |
| AR081653A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR080056A1 (es) | Derivados de ciclohexil-amida como antagonistas de los receptores de crf | |
| PE20142081A1 (es) | Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed, e.g., due to non-payment of fee |